Comments
The South African drug regulator has rejected the Russian-made Covid-19 vaccine Sputnik V, citing some safety concerns the manufacturer wasn't able to answer.
The South African Health Products Regulatory Authority, or SAHPRA, said in a statement Tuesday that the request for Sputnik V to be authorised could “not be approved at this time,” referring to past failed HIV vaccines that used a similar technology.
A late-stage study published in the journal Lancet last year in more than 20,000 participants found that Sputnik V was safe and about 91 per cent effective in preventing people from becoming severely ill with Covid-19.
Adenovirus concerns
Sputnik V uses two types of harmless viruses known as adenoviruses to carry the spike protein into the body, which then primes the immune system to produce antibodies against Covid-19. SAHPRA said concerns have been raised about the safety of Adenovirus Type 5, which is used in one of the Sputnik V doses. The other dose contains Adenovirus Type 26, which is also used by Johnson & Johnson.
South African officials pointed to two failed research studies testing an HIV vaccine also using Adenovirus Type 5, which found men who were vaccinated had a higher risk of being infected with HIV. The regulators said they had asked the Russian makers of Sputnik V to provide data proving the vaccine's safety in a country with high rates of HIV but that “the applicant was not able to adequately address (their) request.” Dr. Julian Tang, a virologist at Britain's University of Leicester, was perplexed by the decision.
“It's a strange connection to make,” he said, explaining that while past concerns have been raised about using the particular virus vector in Sputnik V, much remains uncertain. “It's not the vector that caused HIV so you can't just blame it on that,” Tang said.
The vaccine made by AstraZeneca uses a related chimpanzee adenovirus; both it and the Johnson & Johnson shot have been approved in South Africa.
The Russian makers of Sputnik V, the Gamaleya Institute, couldn't immediately be reached for comment. Amid widespread vaccine hesitancy in Russia, authorities have struggled to convince people to get vaccinated and the immunisation rate in the country has remained stubbornly low, at about 32 per cent, despite availability of Sputnik V.
Sputnik V is currently also being considered for authorisation by the World Health Organization and the European Medicines Agency. The shot has been given the green light in more than 70 countries. To date, no significant safety problems have been identified.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.